Morgan Stanley Keeps Their Hold Rating on Biogen (BIIB)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Biogen today and set a price target of $200.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Flynn is a 5-star analyst with an average return of 9.8% and a 56.21% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Moderna.
In addition to Morgan Stanley, Biogen also received a Hold from Barclays’s Emily Field in a report issued on April 2. However, on April 7, RBC Capital maintained a Buy rating on Biogen (NASDAQ: BIIB).
Based on Biogen’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.28 billion and a GAAP net loss of $48.41 million. In comparison, last year the company earned a revenue of $2.45 billion and had a net profit of $266.7 million
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BIIB in relation to earlier this year. Most recently, in February 2026, Priya Singhal, the Head of Development of BIIB sold 2,660.00 shares for a total of $531,547.80.
Read More on BIIB:
Disclaimer & DisclosureReport an Issue
- Biogen price target lowered to $213 from $233 at RBC Capital
- Biogen expects Q1 results to include $34M expense on pre-tax basis
- Biogen price target raised to $237 from $228 at H.C. Wainwright
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Biogen price target raised to $275 from $250 at Oppenheimer
